ProQR Therapeutics (NASDAQ:PRQR) Given Consensus Recommendation of “Hold” by Analysts

ProQR Therapeutics (NASDAQ:PRQRGet Rating) has been assigned a consensus rating of “Hold” from the ten analysts that are presently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and four have assigned a buy recommendation to the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $5.83.

A number of equities analysts recently commented on the stock. Chardan Capital reduced their price objective on shares of ProQR Therapeutics from $8.00 to $2.50 and set a “buy” rating for the company in a research note on Thursday, April 14th. Raymond James downgraded shares of ProQR Therapeutics from a “strong-buy” rating to a “market perform” rating in a research note on Friday, February 11th. Cantor Fitzgerald reduced their price objective on shares of ProQR Therapeutics from $6.00 to $3.50 in a research note on Tuesday, April 19th. HC Wainwright reduced their price objective on shares of ProQR Therapeutics from $20.00 to $4.00 and set a “buy” rating for the company in a research note on Monday, February 14th. Finally, Citigroup downgraded shares of ProQR Therapeutics from a “buy” rating to a “hold” rating in a research note on Sunday, February 13th.

Shares of ProQR Therapeutics stock traded down $0.01 on Friday, hitting $0.73. 1,690 shares of the company traded hands, compared to its average volume of 1,688,031. The stock’s 50 day moving average price is $0.93 and its 200-day moving average price is $4.73. The company has a current ratio of 6.94, a quick ratio of 5.10 and a debt-to-equity ratio of 0.35. ProQR Therapeutics has a 52 week low of $0.70 and a 52 week high of $9.09. The company has a market cap of $36.44 million, a PE ratio of -0.64 and a beta of 0.85.

ProQR Therapeutics (NASDAQ:PRQRGet Rating) last posted its quarterly earnings results on Thursday, February 24th. The biopharmaceutical company reported ($0.30) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.26) by ($0.04). ProQR Therapeutics had a negative net margin of 4,113.78% and a negative return on equity of 59.74%. The company had revenue of $0.27 million for the quarter, compared to the consensus estimate of $0.90 million. As a group, research analysts anticipate that ProQR Therapeutics will post -0.96 EPS for the current fiscal year.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in PRQR. US Bancorp DE grew its holdings in shares of ProQR Therapeutics by 122.1% during the third quarter. US Bancorp DE now owns 3,693 shares of the biopharmaceutical company’s stock valued at $31,000 after buying an additional 2,030 shares during the last quarter. Northern Trust Corp purchased a new stake in shares of ProQR Therapeutics during the fourth quarter valued at $51,000. Dorsey Wright & Associates purchased a new stake in shares of ProQR Therapeutics during the fourth quarter valued at $55,000. ProShare Advisors LLC purchased a new stake in shares of ProQR Therapeutics during the fourth quarter valued at $80,000. Finally, Coastal Bridge Advisors LLC purchased a new stake in shares of ProQR Therapeutics during the fourth quarter valued at $85,000. 95.47% of the stock is currently owned by institutional investors and hedge funds.

ProQR Therapeutics Company Profile (Get Rating)

ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It is primarily developing sepofarsen that is in phase II/III illuminate trial for treating leber's congenital amaurosis 10 disease; QR-421a, which is in phase I/II stellar trial for usher syndrome type 2 and non-syndromic retinitis pigmentosa; QR-1123 that is in phase I/II aurora trial for the treatment of autosomal dominant retinitis pigmentosa; and QR-504a, which is in first clinical trial for the treatment of fuchs endothelial corneal dystrophy.

Further Reading

Analyst Recommendations for ProQR Therapeutics (NASDAQ:PRQR)

Receive News & Ratings for ProQR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.